Future myocardial infarction after an acute coronary syndrome and pharmacogenetic response to dalcetrapib
Article 2025 en
Authors
JT
Jean‐Claude Tardif
MP
Marc A. Pfeffer
SK
Simon Kouz
Abstract
1 min read
Despite guideline directed therapy following ACS, history of prior coronary events and on-treatment LDL-C, A1c, hs-CRP and blood pressure remain determinants of future MI. In the Dal-GenE AA genotype patients, dalcetrapib reduced the rate of MI, independently of those variables. The Dal-GenE 2 trial is designed to confirm this pharmacogenetic hypothesis.
Jean‐Claude Tardif, Marie‐Pierre Dubé, Marc A. Pfeffer, David D. Waters, Wolfgang Köenig, Aldo Maggioni, John J.V. McMurray, Vincent Mooser, Harvey D. White, Therèse Heinonen, Donald M. Black, Marie‐Claude Guertin
Jean‐Claude Tardif, Marc A. Pfeffer, Simon Kouz, Wolfgang Köenig, Aldo Maggioni, John J.V. McMurray, David D. Waters, Jean C. Grégoire, Philippe L. L’Allier, J. Wouter Jukema, Harvey D. White, Therèse Heinonen, David Kallend, Fouzia Laghrissi‐Thode, Annik Fortier, Marie‐Claude Guertin, Marie‐Pierre Dubé
Michelle L. O’Donoghue, Eugene Braunwald, Harvey D. White, Dylan P. Steen, Mary Ann Lukas, Elizabeth Tarka, Philippe Gabríel Steg, Judith S. Hochman, Christoph Bode, Aldo P. Maggioni, KyungAh Im, Jennifer B. Shannon, Richard Y. Davies, Sabina A. Murphy, Sharon Crugnale, Stephen D. Wiviott, Marc P. Bonaca, David F. Watson, W. Douglas Weaver, Patrick W. Serruys, Christopher P. Cannon
Dietrich Rothenbacher, Raphael S. Peter, Raphael S. Peter, A. Jaensch, Andreas Rehm, Petra Schubert, Ben Schoettker, Ute Mons, Wolfgang Köenig, Hermann Brenner
Discussion(0)
No comments yet. Be the first to comment.